Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

BACKGROUND: Optimal drug treatment for patients with resistant hypertension is undefined. We aimed to test the hypotheses that resistant hypertension is most often caused by excessive sodium retention, and that spironolactone would therefore be superior to non-diuretic add-on drugs at lowering blood...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lancet
Hauptverfasser: Williams, Bryan, MacDonald, Thomas M, Morant, Steve, Webb, David J, Sever, Peter, McInnes, Gordon, Ford, Ian, Cruickshank, J Kennedy, Caulfield, Mark J, Salsbury, Jackie, Mackenzie, Isla, Padmanabhan, Sandosh, Brown, Morris J
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2015
Schlagworte:
Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4655321/
https://ncbi.nlm.nih.gov/pubmed/26414968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(15)00257-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge